Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay

Sensitive bioanalytical methods are required for pharmacokinetic studies in children, due to the small volume and modest number of samples that can be obtained. We sought to develop a LC–MS assay for primaquine and its active metabolite, carboxyprimaquine, following simultaneous, solid phase extract...

Full description

Bibliographic Details
Main Authors: Page-Sharp, Madhu, Ilett, K., Betuela, I., Davis, T., Batty, Kevin
Format: Journal Article
Published: Elsevier 2012
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/40766
_version_ 1848755959087759360
author Page-Sharp, Madhu
Ilett, K.
Betuela, I.
Davis, T.
Batty, Kevin
author_facet Page-Sharp, Madhu
Ilett, K.
Betuela, I.
Davis, T.
Batty, Kevin
author_sort Page-Sharp, Madhu
building Curtin Institutional Repository
collection Online Access
description Sensitive bioanalytical methods are required for pharmacokinetic studies in children, due to the small volume and modest number of samples that can be obtained. We sought to develop a LC–MS assay for primaquine and its active metabolite, carboxyprimaquine, following simultaneous, solid phase extraction of both analytes from human plasma. The analysis was conducted on a single-quad LC–MS system (Shimadzu Model 2020) in ESI+ mode, with quantitation by selected ion monitoring. Primaquine, carboxyprimaquine and 8-aminoquinoline (internal standard) were separated using a mobile phase of 80:20 methanol:water with 0.1% (v/v) formic acid and a Luna C18 HPLC column, at ambient temperature. Solid phase extraction of the analytes from plasma (0.5 mL) was achieved with Oasis® HLB cartridges. The retention times for primaquine, 8-aminoquinoline and carboxyprimaquine were 3.3, 5.7 and 8.5 min, respectively. The calibration curve range (2–1500 μg/L) was appropriate for the limits of quantification and detection for primaquine (2 μg/L and 1 μg/L, respectively) and carboxyprimaquine (2.5 μg/L and 1 μg/L) and the anticipated plasma concentrations of the analytes. Intra- and inter-day precision for both primaquine and carboxyprimaquine was <10% across the concentration range 5–1000 μg/L. Accuracy for both analytes was <15% (5–500 μg/L). This validated LC–MS method with solid phase extraction facilitates the simultaneous analysis of primaquine and carboxyprimaquine from small volumes of human plasma, with run time <10 min, recovery >85% and sensitivity of 1–2 μg/L.
first_indexed 2025-11-14T09:04:35Z
format Journal Article
id curtin-20.500.11937-40766
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:04:35Z
publishDate 2012
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-407662017-09-13T16:08:57Z Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay Page-Sharp, Madhu Ilett, K. Betuela, I. Davis, T. Batty, Kevin primaquine solid phase extraction plasma carboxyprimaquine LC–MS Sensitive bioanalytical methods are required for pharmacokinetic studies in children, due to the small volume and modest number of samples that can be obtained. We sought to develop a LC–MS assay for primaquine and its active metabolite, carboxyprimaquine, following simultaneous, solid phase extraction of both analytes from human plasma. The analysis was conducted on a single-quad LC–MS system (Shimadzu Model 2020) in ESI+ mode, with quantitation by selected ion monitoring. Primaquine, carboxyprimaquine and 8-aminoquinoline (internal standard) were separated using a mobile phase of 80:20 methanol:water with 0.1% (v/v) formic acid and a Luna C18 HPLC column, at ambient temperature. Solid phase extraction of the analytes from plasma (0.5 mL) was achieved with Oasis® HLB cartridges. The retention times for primaquine, 8-aminoquinoline and carboxyprimaquine were 3.3, 5.7 and 8.5 min, respectively. The calibration curve range (2–1500 μg/L) was appropriate for the limits of quantification and detection for primaquine (2 μg/L and 1 μg/L, respectively) and carboxyprimaquine (2.5 μg/L and 1 μg/L) and the anticipated plasma concentrations of the analytes. Intra- and inter-day precision for both primaquine and carboxyprimaquine was <10% across the concentration range 5–1000 μg/L. Accuracy for both analytes was <15% (5–500 μg/L). This validated LC–MS method with solid phase extraction facilitates the simultaneous analysis of primaquine and carboxyprimaquine from small volumes of human plasma, with run time <10 min, recovery >85% and sensitivity of 1–2 μg/L. 2012 Journal Article http://hdl.handle.net/20.500.11937/40766 10.1016/j.jchromb.2012.06.019 Elsevier restricted
spellingShingle primaquine
solid phase extraction
plasma
carboxyprimaquine
LC–MS
Page-Sharp, Madhu
Ilett, K.
Betuela, I.
Davis, T.
Batty, Kevin
Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay
title Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay
title_full Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay
title_fullStr Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay
title_full_unstemmed Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay
title_short Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay
title_sort simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and lc-ms assay
topic primaquine
solid phase extraction
plasma
carboxyprimaquine
LC–MS
url http://hdl.handle.net/20.500.11937/40766